Raymond James Financial Services Advisors, Inc. Curis Inc Transaction History

Raymond James Financial Services Advisors, Inc.

  • $73.5 Billion
  • Q3 2024

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 25, 2023
SELL
$0.57 - $0.99 $711 - $1,235
-1,248 Reduced 3.91%
30,711 $25,000
Q1 2023

Apr 14, 2023
SELL
$0.51 - $0.78 $15 - $23
-30 Reduced 0.09%
31,959 $19,000
Q4 2022

Feb 08, 2023
BUY
$0.47 - $17.22 $7,147 - $261,864
15,207 Added 90.61%
31,989 $17,000
Q3 2022

Oct 25, 2022
BUY
$0.74 - $15.01 $1,776 - $36,024
2,400 Added 16.69%
16,782 $12,000
Q2 2022

Aug 12, 2022
BUY
$0.71 - $2.43 $10,211 - $34,948
14,382 New
14,382 $14,000
Q3 2021

Nov 02, 2021
SELL
$6.94 - $8.85 $180,322 - $229,949
-25,983 Closed
0 $0
Q2 2021

Aug 11, 2021
SELL
$7.45 - $16.27 $18,625 - $40,675
-2,500 Reduced 8.78%
25,983 $210,000
Q1 2021

May 14, 2021
BUY
$8.78 - $12.8 $17,560 - $25,600
2,000 Added 7.55%
28,483 $322,000
Q4 2020

Feb 12, 2021
BUY
$1.08 - $8.2 $1,404 - $10,659
1,300 Added 5.16%
26,483 $217,000
Q3 2020

Nov 04, 2020
BUY
$0.95 - $1.42 $2,850 - $4,260
3,000 Added 13.52%
25,183 $29,000
Q2 2020

Jul 17, 2020
BUY
$0.63 - $1.7 $13,975 - $37,711
22,183 New
22,183 $27,000

About CURIS INC

CRIS Quotes by TradingView
  • Ticker CRIS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 91,814,704
  • Market Cap $409M
  • Description
  • Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...
More about CRIS
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email